Sam Lee | President
Cocrystal Pharma, Inc.

Sam Lee, President, Cocrystal Pharma, Inc.

Sam Lee, Ph.D., is President, Interim Co-CEO and co-founder of Cocrystal Pharma Inc., Bothell, Washington, founded in 2007.  Cocrystal Pharma Inc. (NASDAQ: COCP) is developing novel small molecule antivirals for the treatment of COVID-19, Influenza, Norovirus, and Hepatitis C.  He served on the Board of Directors of Cocrystal Discovery Inc., from 2007 to 2014.  Prior to his work at Cocrystal, he managed anti-infective, oncology, and inflammation programs at Icos Corporation, and was also responsible for bringing unique protein crystallography and structural screening technologies to Icos research.  Also, he played a key role in developing phosphoinositide 3-kinase (PI3K) delta inhibitors at Icos, which ultimately yielded an FDA approved product.  Prior to Icos, he founded and was CEO of Viral Assays, Inc., in Cupertino, CA, licensing patented technologies to major pharmaceutical companies. He received his Ph.D. from the University of Notre Dame and completed postdoctoral training at the Department of Biochemistry at Stanford Medical School


WVIC/WAC Day 3 - Dec 1 @ 10:40

Novel broad-spectrum influenza A PB2 inhibitor: clinical update

last published: 01/Dec/22 17:25 GMT

back to speakers

For conference programme and speaking opportunities:
Lauren Sheppard

For sponsorship and exhibition opportunities:
Thomas Hall